医学
奥克列珠单抗
结肠炎
不良事件报告系统
溃疡性结肠炎
美罗华
炎症性肠病
不利影响
内科学
易普利姆玛
纳塔利祖玛
免疫学
免疫系统
淋巴瘤
疾病
免疫疗法
作者
Tiffany Kim,Allen Brinker,David Croteau,Paul R. Lee,Laura Baldassari,J. C. Stevens,Alice Hughes,Juli Tomaino,Arushi M. deFonseka,Tara Altepeter,Cindy Kortepeter
标识
DOI:10.1177/13524585231195854
摘要
An association between certain immunomodulatory therapies (rituximab, ipilimumab, and other immune checkpoint inhibitors) and inflammatory (non-ischemic and non-infectious) colitis in oncologic and non-oncologic patient populations is well documented in the medical literature.The purpose of this case series is to describe adverse event reports of new onset, inflammatory colitis in association with ocrelizumab in patients with multiple sclerosis submitted to U.S. Food and Drug Administration (FDA) or published in the medical literature.The FDA Adverse Event Reporting System (FAERS) and medical literature were searched.A review of postmarketing cases from FAERS and published medical literature identified 38 cases consistent with inflammatory, non-ischemic, and non-infectious colitis in association with ocrelizumab. The median time-to-onset was 8 months. Cases were reported using the following diagnostic terms: Crohn's disease (13), unspecified colitis (11), microscopic colitis (5), ulcerative colitis (5), medication-induced colitis (3), and autoimmune colitis (2).This case series highlights ocrelizumab induced immune-mediated colitis that can be clinically severe and potentially life-threatening. Based on the findings of this review, the ocrelizumab Prescribing Information was amended to include immune-mediated colitis in the Warnings and Precautions section.
科研通智能强力驱动
Strongly Powered by AbleSci AI